Clinical trials

Condition   Drug Name  
Study Adalimumab vs. methotrexate in psoriasis: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study
Design Randomized; Double-blind
Patients 271
Treatment Regimen Adalimumab, 80 mg s.c. --> 40 mg s.c. 1x/2 wks x 15 wks; Methotrexate, 25 [max.] mg/wk p.o. x 16 wks; Placebo
Conclusions Statistically significant changes in the Dermatology-specific Quality Of Life scores were seen with adalimumab compared to methotrexate and placebo in chronic plaque psoriasis patients
Reference(s) Improvement in dermatology-specific quality of life with adalimumab treatment: Results from CHAMPION
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1147.
Author and Affiliation Langley, R.G., Saurat, J., Van de Kerkhof, P., Mrowietz, U., Okun, M.